2022-04-142022-04-142009-09Başkan, E. B. vd. (2009). "Orta-şiddetli psoriazisli olgularda infliksimab ile klinik deneyimimiz: Retrospektif çalışma". Türkderm Deri Hastalıkları ve Frengi Arşivi, 43(3), 95-99.1019-214X1308-6294https://jag.journalagent.com/turkderm/pdfs/TURKDERM_43_3_95_99.pdfhttp://hdl.handle.net/11452/25789Background and Design: In this study, we aimed to evaluate the efficacy, safety and side effects of infliximab therapy in patients followed up in our clinic with moderate-severe psoriatic patients unresponsive to conventional therapies. Material and Method: Twenty-six psoriasis patients who were given infliximab therapy in our clinic between years 20062008, were retrospectively analyzed for their demographical clinical features, changes in PASI score, duration, efficacy and adverse effects of the therapy. Results: There were 15 female and 11 male psoriasis patients; ages ranging from 18 to 70 years (45.2 +/- 12.9). 17 of them were diagnosed as generalize plaque type psoriasis, 2 as eritrodermic psoriasis, 5 as generalize pustular, two of them as palmoplantar pustular psoriasis. Thirteen have associated psoriatic arthritis. All patients received 5 mg/kg intravenous infliximab infusion at weeks 0, 2, and 6, followed by every 8 weeks. Number of infliximab therapy sections was ranging from 2 to 16 and duration of treatment from 1 month to 28 months. Improvement in PASI between pretreatment and after induction therapy was statistically significant (p<0.05). Additional systemic treatment for disease activation was applied to patients receiving infliximab monotherapy at 14.-38. weeks. We observed allergic infusion reactions in 15.4% of the patients. Conclusion: In compatible with data in literature, we found that infliximab therapy provides a rapid clinical response in patients (generalized, eritrodermic and/or pustular psoriasis) who are unresponsive to immunosupressive agents or in cases which these treatment modalities cannot be used because of side effects.trinfo:eu-repo/semantics/openAccessInfliximabPsoriasisTNF-alphaNecrosis-factor-alphaTnf-alphaPustular psoriasisArthritisEtanerceptEfficacyTherapyDermatologyArticle0002700341000042-s2.0-730490998739599433DermatologyPustulosis Palmoplantaris; Ustekinumab; EtanerceptInfliximabAdultAgedArticleClinical articleClinical featureDisease activityDisease severityDrug efficacyDrug hypersensitivityDrug infusionDrug safetyFemaleHumanMaleMonotherapyPsoriasisPsoriatic arthritisRetrospective studySystemic therapyTreatment duration